|Chemical and physical data|
|Molar mass||408.534 g/mol|
|3D model (Jmol)|
|(what is this?)|
Omapatrilat (INN, tentative trade name Vanlev) is an antihypertensive agent that inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.
Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin-converting enzyme (ACE), and neprilysin (neutral endopeptidase), both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction.
The drug was promoted for possible uses in congestive heart failure.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 40" (PDF). World Health Organization. p. 190. Retrieved 2 March 2017.
- Venugopal, J (2 March 2005). "Pharmacological Modulation of the Natriuretic Peptide System". Expert Opinion on Therapeutic Patents. 13 (9): 1389–1409. doi:10.1517/135437188.8.131.529.
- Liao, WC; Vesterqvist, O; Delaney, C; Jemal, M; Ferreira, I; Ford, N; Swanson, B; Uderman, H (October 2003). "Pharmacokinetics and Pharmacodynamics of the Vasopeptidase Inhibitor, Omapatrilat in Healthy Subjects". British Journal of Clinical Pharmacology. 56 (4): 395–406. PMC . PMID 12968984.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|